Multiple Myeloma Case Developed During the Use of the Teriparatide
Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their association in the form of case reports has been report...
Saved in:
| Main Authors: | Zehra Erdemir, Ayşe İyiyapıcı Ünübol, Mustafa Ünübol, Esra Ercan Aktekin, İrfan Yavaşoğlu, Engin Güney |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-04-01
|
| Series: | Türk Osteoporoz Dergisi |
| Subjects: | |
| Online Access: |
http://www.turkosteoporozdergisi.org/archives/archive-detail/article-preview/multiple-myeloma-case-developed-during-the-use-of-/51345
|
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial
by: Huan Wang, et al.
Published: (2025-07-01) -
A Rare Cause of Back Pain after Pregnancy: Postpartum Osteoporosis and Treatment Approach
by: Muzaffer İlhan, et al.
Published: (2016-12-01) -
Therapeutic effects of teriparatide on subchondral bone lesions and pain in mono-iodoacetate-induced osteoarthritis rat model
by: Koji Aso, et al.
Published: (2025-09-01) -
DIAGNOSTIC OF NONSECRETORY MULTIPLE MYELOMA (CLINICAL CASE)
by: N. T. Vatutin, et al.
Published: (2017-03-01) -
Pitfalls in the pathological diagnosis of multiple myeloma
by: V. V. Baykov
Published: (2022-11-01)